Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about MT1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Name | MT1 |
| Key Genes/Proteins | AQP4, DDC, LRP1 |
| Related Diseases | Alzheimer's disease, INFLAMMATION |
| Related Pathways | autophagy pathway, blood-brain barrier, circadian regulation |
| Linked Hypotheses | 6 hypotheses |
Knowledge base pages for this entity
graph TD
MT1[MT1]
MT1 -->|regulates| Mitochondrial_Dynamics[Mitochondrial Dynamics]
MT1 -->|involved_in| Neuroprotection[Neuroprotection]
MT1 -->|regulates| Metal_Ion_Homeostasis[Metal Ion Homeostasis]
MT1 -->|inhibits| __synuclein_Aggregation[α-synuclein Aggregation]
MT1 -->|inhibits| Inflammation[Inflammation]
MT1 -.protects against.-> Oxidative_Stress[Oxidative Stress]
MT1 -->|regulates| Tp53[Tp53]
MT1 -->|involved_in| Neurogenesis[Neurogenesis]
MT1 -->|upregulates| Autophagy[Autophagy]
MT1 -->|regulates| mitochondrial_fission[mitochondrial fission]
AQP4[AQP4] -->|activates| MT1
DDC[DDC] -->|activates| MT1
benchmark_ot_ad_answer_key_MT1[benchmark_ot_ad_answer_key:MT1] -->|data_in| MT1| Target | Relation | Type | Str |
|---|---|---|---|
| benchmark_ot_ad_answer_key:MT1 | data_in | dataset_row | 0.00 |
| Neuroprotection | involved_in | process | 0.95 |
| Mitochondrial Dynamics | regulates | process | 0.95 |
| α-synuclein Aggregation | inhibits | process | 0.90 |
| Metal Ion Homeostasis | regulates | process | 0.90 |
| Inflammation | inhibits | process | 0.90 |
| Parkinson's Disease | associated_with | disease | 0.90 |
| Oxidative Stress | protects_against | process | 0.90 |
| Autophagy | upregulates | process | 0.85 |
| Neurogenesis | involved_in | process | 0.85 |
| Tp53 | regulates | entity | 0.85 |
| mitochondrial fission | regulates | process | 0.80 |
| MITOPHAGY | regulates | process | 0.80 |
| ROS | inhibits | phenotype | 0.72 |
| circadian regulation | participates_in | pathway | 0.65 |
| INFLAMMATION | inhibits | phenotype | 0.64 |
| NEURODEGENERATION | inhibits | disease | 0.64 |
| LRP1 | interacts_with | protein | 0.64 |
| mitochondrial function | participates_in | pathway | 0.60 |
| autophagy pathway | participates_in | pathway | 0.60 |
| neurons | expressed_in | cell_type | 0.60 |
| MTNR1B | expressed_in | gene | 0.60 |
| TH | activates | gene | 0.60 |
| P62 | activates | gene | 0.60 |
| MTNR1A | expressed_in | gene | 0.60 |
| P53 | regulates | protein | 0.56 |
| unfolded protein response | participates_in | pathway | 0.55 |
| astrocytes | expressed_in | cell_type | 0.55 |
| PKA | activates | gene | 0.55 |
| NF-kB signaling | participates_in | pathway | 0.55 |
| Alzheimer's disease | activates | disease | 0.55 |
| stem cells | expressed_in | cell_type | 0.55 |
| blood-brain barrier | participates_in | pathway | 0.55 |
| neurodegeneration | interacts_with | disease | 0.55 |
| PP2A | activates | gene | 0.55 |
| Source | Relation | Type | Str |
|---|---|---|---|
| benchmark_ot_ad_answer_key:MT1 | data_in | dataset_row | 0.00 |
| H7 | high_affinity_agonist_target | hypothesis | 0.00 |
| AQP4 | activates | gene | 0.55 |
| DDC | activates | gene | 0.55 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| p38α Inhibitor and PRMT1 Activator Combination to Restore Ph | 0.879 | neurodegeneration | What is the therapeutic window between i |
| DNMT1-Targeting Antisense Oligonucleotide Reset | 0.648 | neurodegeneration | Epigenetic clocks and biological aging i |
| DNMT1 Compensation Window During Synaptic Resilience Phase | 0.528 | neurodegeneration | What is the optimal therapeutic window d |
| MT1 Receptor Activation at Low Doses Synchronizes Suprachias | 0.405 | - | What is the minimum effective dose of tr |
| Small-Molecule Modulation of G3BP1 Condensate Dynamics via P | 0.400 | neurodegeneration | How do disease-associated mutations in G |
| DNMT1 Downregulation to Correct Genome-Wide Hypomethylation | 0.380 | neurodegeneration | Comparative epigenetic signatures across |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-26 | 7 hypotheses Top: 0.735
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| MAPK pathway inhibition by QTJD through butyrate mechanism | exploratory | Mycoplasma pneumoniae pneumoni | 0.900 | 0.00 | Mouse macrophages | proposed | N/A |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Assessment of Out-of-Pocket Costs for Robotic Cancer Surgery in US Adults. [PMID:31940036] | Nabi J, Friedlander DF, Chen X, Cole AP, | JAMA Netw Open | 2020 | 1 |
| Multidisciplinary Approach to Interstitial Lung Diseases: Nothing Is Better than [PMID:32709146] | Vancheri C, Basile A | Diagnostics (Basel) | 2020 | 1 |
| Higher-Order Inter-chromosomal Hubs Shape 3D Genome Organization in the Nucleus. [PMID:29887377] | Quinodoz SA, Ollikainen N, Tabak B, Pall | Cell | 2018 | 1 |
| Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions. [PMID:28319113] | Shen JP, Zhao D, Sasik R, Luebeck J, Bir | Nat Methods | 2017 | 1 |
| The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation [PMID:20644199] | McKenna A, Hanna M, Banks E, Sivachenko | Genome Res | 2010 | 1 |
| Prevalence of clinical and radiographic signs of osteoarthrosis of the temporoma [PMID:20395464] | Schmitter M, Essig M, Seneadza V, Balke | Dentomaxillofac Radiol | 2010 | 1 |
| Disrupting the epigenetic alliance: structural insights and therapeutic strategi [PMID:40960568] | Kamel EM, Ali MAM, Allam AA, Ahmed NA, A | Functional & integrative genom | 2025 | 0 |
| Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies. [PMID:38345160] | Woost PG, William BM, Cooper BW, Ueda Os | Cytometry. Part B, Clinical cy | 2024 | 0 |
| DNMT1-targeting remodeling global DNA hypomethylation for enhanced tumor suppres [PMID:38755637] | Liu Y, Sun Y, Yang J, Wu D, Yu S, Liu J, | Molecular cancer | 2024 | 0 |
| Bi-functional CpG-STAT3 decoy oligonucleotide triggers multilineage differentiat [PMID:39171140] | Wang D, Kaniowski D, Jacek K, Su YL, Yu | Molecular therapy. Nucleic aci | 2024 | 0 |
| A precise and efficient circular RNA synthesis system based on a ribozyme derive [PMID:37378451] | Cui J, Zhang L, Zhang Z, Luo X, Liu Y, L | Nucleic acids research | 2023 | 0 |
| Channel branching and zigzagging in negative cloud-to-ground lightning. [PMID:28615706] | ["Jiang R", "Qie X", "Zhang H", "Liu M", | Scientific reports | 2017 | 0 |
| Sequential transcriptional waves direct the differentiation of newborn neurons i [PMID:26940868] | ["Telley L", "Govindan S", "Prados J", " | Science (New York, N.Y.) | 2016 | 0 |
| Incorporating theology into medical education. [PMID:23209119] | Adam Miller | CMAJ : Canadian Medical Associ | 2013 | 0 |
Multi-agent debates referencing this entity
Hypotheses and analyses mentioning MT1 in their description or question text